Cytokine Profile Associated with Selective Removal of Natural Anti-αGal Antibodies in a Sepsis Model in Gal-KO Mice.
Selective depletion of natural anti-Galα1-3Galβ1-4GlcNAc (so-called anti-αGal) antibodies is achieved in α1,3-galactosyltransferase knockout (Gal-KO) mice by administration of the soluble glycoconjugate of αGal GAS914. This molecule removed up to 90% of natural circulating anti-αGal antibodies without causing unspecific production of cytokines in wild-type (CBA) and Gal-KO mice. However, the removal of anti-αGal antibodies in Gal-KO mice with GAS914 in the context of sepsis after cecal ligation and puncture (CLP) was associated with a significant increase in the production of leptin, CXLC1, CXLC13, and TIMP-1 cytokines compared to vehicle (PBS)-treated controls. Despite the current lack of understanding of the underlying mechanism, our data suggest a putative role of natural anti-αGal antibodies in the regulation of some cytokines during sepsis.
Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, 08908, Spain.
Magdiel
M
Pérez-Cruz
Daniel
D
Bello-Gil
Cristina
C
Costa
Rafael
R
Mañez
D000818:Animals; D001323:Autoantibodies / Q000097:blood*; D016207:Cytokines / Q000097:blood*; D004195:Disease Models, Animal; D005700:Galactosyltransferases / Q000172:deficiency*; D051379:Mice; D018345:Mice, Knockout; D018805:Sepsis / Q000097:blood* / Q000235:genetics; D014312:Trisaccharides / Q000494:pharmacology*
D001323:Autoantibodies; D016207:Cytokines; D014312:Trisaccharides; C076569:alpha-galactosyl epitope; D005700:Galactosyltransferases; C487611:alpha 1,3 galactosyltransferase, mouse